These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 28343810)
1. Policy objective of generic medicines from the investment perspective: The case of clopidogrel. Elek P; Harsányi A; Zelei T; Csetneki K; Kaló Z Health Policy; 2017 May; 121(5):558-565. PubMed ID: 28343810 [TBL] [Abstract][Full Text] [Related]
2. Generic clopidogrel: time to substitute? Doll J; Zeitler E; Becker R JAMA; 2013 Jul; 310(2):145-6. PubMed ID: 23839745 [No Abstract] [Full Text] [Related]
3. [Scope of the contract for drug therapy. Rebate contracts also for original drugs]. MMW Fortschr Med; 2009 Jul; 151(30-33):80. PubMed ID: 19722473 [No Abstract] [Full Text] [Related]
4. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. Kaplan WA; Ritz LS; Vitello M; Wirtz VJ Health Policy; 2012 Aug; 106(3):211-24. PubMed ID: 22694970 [TBL] [Abstract][Full Text] [Related]
5. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England. Mansfield SJ Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618 [TBL] [Abstract][Full Text] [Related]
6. The market dynamics of generic medicines in the private sector of 19 low and middle income countries between 2001 and 2011: a descriptive time series analysis. Kaplan WA; Wirtz VJ; Stephens P PLoS One; 2013; 8(9):e74399. PubMed ID: 24098644 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome. Coleman CI; Limone BL Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863 [TBL] [Abstract][Full Text] [Related]
8. A comparison of generic drug prices in seven European countries: a methodological analysis. Wouters OJ; Kanavos PG BMC Health Serv Res; 2017 Mar; 17(1):242. PubMed ID: 28359273 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840 [TBL] [Abstract][Full Text] [Related]
10. Comparison of original and generic clopidogrel 600 mg loading dose in the patients who planned undergoing coronary angiography. Srimahachota S; Rojnuckarin P; Udayachalerm W; Buddhari W; Chaipromprasit J; Lertsuwunseri V; Akkawat B; Jirapattrathamrong S J Med Assoc Thai; 2012 Dec; 95(12):1495-500. PubMed ID: 23390778 [TBL] [Abstract][Full Text] [Related]
11. Variable access to clopidogrel in a harmonized EU market. Stolk P; Belitser SV; Leufkens HG; Heerdink ER Value Health; 2008; 11(5):989-95. PubMed ID: 18489520 [TBL] [Abstract][Full Text] [Related]
12. Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability. Dylst P; Vulto A; Simoens S Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):33-42. PubMed ID: 25138241 [TBL] [Abstract][Full Text] [Related]
13. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO Value Health; 2012; 15(5):664-73. PubMed ID: 22867775 [TBL] [Abstract][Full Text] [Related]
14. Encouraging the use of generic medicines: implications for transition economies. King DR; Kanavos P Croat Med J; 2002 Aug; 43(4):462-9. PubMed ID: 12187525 [TBL] [Abstract][Full Text] [Related]
15. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770 [TBL] [Abstract][Full Text] [Related]
17. Societal value of generic medicines beyond cost-saving through reduced prices. Dylst P; Vulto A; Simoens S Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):701-11. PubMed ID: 25695926 [TBL] [Abstract][Full Text] [Related]
18. [Price differences between generic and innovator medicines in Brazil]. Vieira FS; Zucchi P Rev Saude Publica; 2006 Jun; 40(3):444-9. PubMed ID: 16810368 [TBL] [Abstract][Full Text] [Related]
19. Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses. Leopold C; Zhang F; Mantel-Teeuwisse AK; Vogler S; Valkova S; Ross-Degnan D; Wagner AK Int J Equity Health; 2014 Jul; 13():53. PubMed ID: 25062657 [TBL] [Abstract][Full Text] [Related]
20. Analysis of French generic medicines retail market: why the use of generic medicines is limited. Dylst P; Vulto A; Simoens S Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):795-803. PubMed ID: 25095903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]